TY - JOUR
AU - Kato, Norihiko
AB - Abstract In this study, we investigated the effect of the antitumor necrosis factor alpha (anti-TNF-α) antibody, infliximab, combined with methotrexate (MTX) and MTX alone on the serum levels of interleukin (IL)-23 and IL-17 in rheumatoid arthritis (RA) patients. Infliximab combined with MTX was administered to 26 patients with RA (infliximab group), and MTX alone was given to 20 patients with RA (MTX group). We evaluated clinical and laboratory parameters, including the Disease Activity Scores of 28 joints (DAS28) and serum levels of IL-23 and IL-17 at baseline and at 14 and 30 weeks after the initial treatment with these drugs. Single regression analysis was performed between the levels of serum IL-23 and other clinical and laboratory parameters at baseline before the initial treatment with infliximab or MTX. A significant reduction of DAS28 scores was observed in both the infliximab and the MTX group at 14 and 30 weeks after the initial treatment. A significant decrease in serum levels of IL-23 was observed in the infliximab group but not in the MTX group at 14 and 30 weeks after the initial treatment. Serum IL-17 levels did not show a significant change during the follow-up period. At baseline, before the initial treatment with infliximab or MTX, serum IL-23 levels showed a significant correlation with DAS28 and the number of swollen joints. This study indicated that the reduction of serum IL-23 levels in RA patients was a novel action of infliximab. Rheumatoid arthritis, Infliximab, Interleukin-23, Interleukin-17 References Arend WP , Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995 ; 38: 151 – 60 . Maini RN , Taylor PC. Anti-cytokine therapy for rheumatoid arthritis . Ann Rev Med . 2000 ; 51 : 207 – 29 . Google Scholar Crossref Search ADS PubMed WorldCat Ingegnoli F , Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade . J Autoimmun . 2008 ; 31 : 175 – 9 . Google Scholar Crossref Search ADS PubMed WorldCat Pittoni V , Bombardieri M, Spinelli FR, Scrivo R, Alessandri C, Conti F, et al. Anti-tumor necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13 . Ann Rheum Dis . 2002 ; 61 : 723 – 5 . Google Scholar Crossref Search ADS PubMed WorldCat Klimiuk PA , Sierakowski S, Domyslawska I, Chwiecko J. Effect of repeated infliximab therapy on serum matrix metalloprotein-ases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis . J Rheumatol . 2004 ; 31 : 238 – 42 . Google Scholar PubMed OpenURL Placeholder Text WorldCat Levälampi T , Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E . Effects of infliximab on cytokines, myelo-peroxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol . 2007 ; 36 : 189 – 93 . Google Scholar OpenURL Placeholder Text WorldCat Haworth C , Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha . Eur J Immunol . 1991 ; 21 : 2575 – 9 . Google Scholar Crossref Search ADS PubMed WorldCat Kageyama Y , Takahashi M, Torikai E, Suzuki M, Ichikawa T, Nagafusa T, et al. Treatment with anti-TNF-alpha antibody inf-liximab reduces serum IL-15 levels in patients with rheumatoid arthritis . Clin Rheumatol . 2007 ; 26 : 505 – 9 . Google Scholar Crossref Search ADS PubMed WorldCat Torikai E , Kageyama Y, Suzuki M, Ichikawa T, Nagano A . The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol . 2007 ; 26 : 1088 – 93 . Google Scholar OpenURL Placeholder Text WorldCat Kikly K , Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation . Curr Opin Immunol . 2006 ; 18 : 670 – 5 . Google Scholar Crossref Search ADS PubMed WorldCat Brentano F , Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: dif-ferential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis . Ann Rheum Dis . 2009 ; 68 : 143 – 50 . Google Scholar Crossref Search ADS PubMed WorldCat Spanakis E , Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab . J Rheumatol . 2006 ; 33 : 2440 – 6 . Google Scholar PubMed OpenURL Placeholder Text WorldCat Kim HR , Kim HS, Park MK, Cho ML, Lee SH, Kim HY. The clinical role of IL-23p19 in patients with rheumatoid arthritis . Scand J Rheumatol . 2007 ; 36 : 259 – 64 . Google Scholar Crossref Search ADS PubMed WorldCat Mitoma H , Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha . Gastroenterology . 2005 ; 128 : 376 – 92 . Google Scholar Crossref Search ADS PubMed WorldCat Kinne RW , Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR . Macrophages in rheumatoid arthritis. Arthritis Res . 2000 ; 2 : 189 – 202 . Google Scholar OpenURL Placeholder Text WorldCat Murphy CA , Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiin-flammatory roles for IL-23 and IL-12 in joint autoimmune inflammation . J Exp Med . 2003 ; 198 : 1951 – 7 . Google Scholar Crossref Search ADS PubMed WorldCat Chen L , Wei XQ, Evans B, Jiang W, Aeschlimann D. IL-23 promotes osteoclast formation by up-regulation of receptor acti-vator of NF-kappa B (RANK) expression in myeloid precursor cells. Eur J Immunol. 2008 ; 38: 2845 – 54 . Atkins GJ , Haynes DR, Geary SM, Loric M, Crotti TN, Findlay DM. Coordinated cytokine expression by stromal and hemato-poietic cells during human osteoclast formation . Bone . 2000 ; 26 : 653 – 6 . Google Scholar Crossref Search ADS PubMed WorldCat Kotake S , Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis . J Clin Invest . 1999 ; 103 : 1345 – 52 . Google Scholar Crossref Search ADS PubMed WorldCat Kolls JK , Linden A. Interleukin-17 family members and inflam-mation . Immunity . 2004 ; 21 : 467 – 76 . Google Scholar Crossref Search ADS PubMed WorldCat Cua DJ , Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain . Nature . 2003 ; 421 : 744 – 8 . Google Scholar Crossref Search ADS PubMed WorldCat Listing J , Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum . 2008 ; 58 : 667 – 77 . Kageyama Y , Ichikawa T, Nagafusa T, Torikai E, Shimazu M, Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis . Rheumatol Int . 2008 ; 28 : 137 – 43 . Google Scholar Crossref Search ADS WorldCat Happel KI , Zheng M, Young E, Quinton LT, Lockhart E, Ramsay AJ, et al. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection . J Immunol . 2003 ; 170 : 4432 – 6 . Google Scholar Crossref Search ADS PubMed WorldCat Ziolkowska M , Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 pro-duction via cyclosporin A-sensitive mechanism. J Immunol. 2000 ; 164 :2832 – 8 . This content is only available as a PDF. © 2009 Japan College of Rheumatology This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) © 2009 Japan College of Rheumatology
TI - Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis
JF - Modern Rheumatology
DO - 10.3109/s10165-009-0217-6
DA - 2009-12-01
UR - https://www.deepdyve.com/lp/oxford-university-press/infliximab-treatment-reduces-the-serum-levels-of-interleukin-23-in-KeqQfp8fCA
SP - 657
EP - 662
VL - 19
IS - 6
DP - DeepDyve
ER -